Cerenome, Inc. CNSY
0.70 USD 0.00 (-0.62%)
Regular-session close
0.69 -0.01 -1.99%
After hours · Nov 19, 5:35 PM ET
0.67 Day range 0.7835
0.43 52-week range 19.00
- YTD
- -94.49%
- 1 year
- -94.27%
News
benzinga.com NVIDIA To $230? Here Are 10 Top Analyst Forecasts For Wednesday Wall Street analysts adjusted targets for HD, DUOT, CNSY, ECL, DLB, NVDA and KLAR, while maintaining their existing ratings.benzinga.com HC Wainwright & Co. Maintains Buy on Cerenome, Raises Price Target to $7 HC Wainwright & Co. analyst Sean Lee maintains Cerenome (NASDAQ:CNSY) with a Buy and raises the price target from $1 to $7.
seekingalpha.com Cerenome, Inc. (CNSY) Q3 2026 Earnings Call Transcript Cerenome, Inc. ( CNSY ) Q3 2026 Earnings Call November 16, 2026 8:30 AM EST Company Participants Marc Hedrick - President, CEO & Director Eric Daniels - Chief Development Officer & COO Russell…benzinga.com Cerenome Announced Interim Data From Its Ongoing ReSPECT-LM Study Of Repeated Intraventricular Dosing Of REYOBIQ; No Dose-Limiting Toxicities Or Adverse Events Leading To Treatment Discontinuation Have Been Reported Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted radiopharmaceuticals, and artificial
globenewswire.com Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting HOUSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company advancing an integrated platform that combines precision diagnostics,…
zacks.com Cerenome (CNSY) Reports Q3 Loss, Beats Revenue Estimates Cerenome (CNSY) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $1 per share a year ago.benzinga.com Cerenome Q3 EPS $(1.14) Misses $(0.95) Estimate, Sales $722.000K Miss $920.333K Estimate Cerenome (NASDAQ:CNSY) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(0.95) by 20 percent. This is a 10.68 percent decrease over losses of $(1.03) per…
globenewswire.com Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company advancing an integrated platform that combines precision diagnostics,…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Cerenome (NASDAQ:CNSY) shares rose 39.5% to $1.07 during Friday's regular session. The market value of their outstanding shares is at $5.8 million. As per the press release, Q3 earnings came…
globenewswire.com Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16 HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence,…
globenewswire.com Cerenome Appoints Director Ron Andrews as Chief Business Officer HOUSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence,…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma…benzinga.com CNSide Diagnostics Inks National In-Network Laboratory Ancillary Provider With Aetna Health Plans CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), announced today that it has entered into a national in-network laboratory ancillary
globenewswire.com Cerenome Secures National In-Network Agreement with Aetna for CNSide® Cerenome now contracted with approximately 85% of private payers in the US, representing approximately 190 million covered lives
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Curis (NASDAQ:CRIS) stock increased by 25.6% to $0.83 during Tuesday's regular session. The company's market cap stands at $1.6 million. Pasithea Therapeutics (NASDAQ:KTTA) shares increased…
globenewswire.com Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma Topline data expected in mid-2027 Previously reported interim Phase 2 data showed a 63% improvement in median overall survival versus standard of care in recurrent glioblastoma (13 months vs. 8…benzinga.com Cerenome To Report Poster Presentation Of Interim Data From Its Current ReSPECT-LMM Multidose Trial Of REYOBIQ At 31st Annual Meeting And Education Day Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence today announced that a poster presentation of…
globenewswire.com Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases Company to provide latest clinical trial data and highlight evolving approaches to leptomeningeal metastases diagnosis and treatment in a company sponsored symposium 2026 SNO Annual Meeting to be…
zacks.com New Strong Sell Stocks for October 22nd CANG, CDZI and CNSY have been added to the Zacks Rank #5 (Strong Sell) List on October 22, 2026.benzinga.com Cerenome Presents New Preclinical Data At 16th Biennial Rivkin Ovarian Cancer Research Symposium Regarding Immunomodulatory Properties Of REYOBIQ Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company") today announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging
globenewswire.com Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™ Findings suggest a dual mechanism of action for REYOBIQ against cancer cells New findings revealed potential dual mechanism as combinations with checkpoint blockade further enhanced REYOBIQ…
zacks.com New Strong Sell Stocks for October 15th CDZI, CNSY and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2026.
globenewswire.com Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests Cerenome secures Florida Blue agreement for CNSide tumor cell and molecular tests, expanding contracted payer access to approximately 164M covered lives.
globenewswire.com Cerenome Launches CNSide® CSF Molecular Profile Tests HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced the commercial launch of…
seekingalpha.com Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform Transcript Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform Transcript
globenewswire.com Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30,…
globenewswire.com Cerenome to Hold CNSide® Business Update Call on September 30, 2026 HOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY ) (“Cerenome” or the “Company”), today announced that management will…
globenewswire.com Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY ) (“Cerenome” or the “Company”), announced today that it has signed an…
globenewswire.com Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announces the appointment of…
globenewswire.com Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment Capital will support continued CNSide® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into…
